Company intelligence / Profile preview

NanoMedSyn

Montpellier, Occitanie/Hérault/Montpellier area, Francenanomedsyn.com ↗

Ownership: Private
Development stage: Preclinical

Overview

NanoMedSyn has demonstrated promising biological activity in preclinical models using its proprietary AMFA technology for next-generation enzyme replacement therapy. The company entered a research collaboration with Shire to evaluate potential treatments for lysosomal storage disorders using this platform.

Therapeutic areas: OncologyRare Diseases
Modalities: Enzyme replacement therapies (ERT)Therapeutic antibodiesNanoparticles
Industry: Biotech

Partnerships

Shire plc (now part of Takeda): Research agreement focused on evaluating potential ERTs for lysosomal storage disorders using NanoMedSyn’s proprietary AMFA technology

Beyond the preview

Go deeper on NanoMedSyn.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NanoMedSyn.

Explore the full profile